|
1
|
O'Brien SG, Guilhot F, Larson RA, Gathmann
I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A,
Hughes T, et al: Imatinib compared with interferon and low-dose
cytarabine for newly diagnosed chronic-phase chronic myeloid
leukemia. N Engl J Med. 348:994–1004. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Druker BJ, Guilhot F, O'Brien SG, Gathmann
I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM,
Stone RM, et al: Five-year follow-up of patients receiving imatinib
for chronic myeloid leukemia. N Engl J Med. 355:2408–2417. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tauchi T, Kizaki M, Okamoto S, Tanaka H,
Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, et
al: Seven-year follow-up of patients receiving imatinib for the
treatment of newly diagnosed chronic myelogenous leukemia by the
TARGET system. Leuk Res. 35:585–590. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorel N, Bonnet ML, Guillier M, Guilhot F,
Brizard A and Turhan AG: Evidence of ABL-kinase domain mutations in
highly purified primitive stem cell populations of patients with
chronic myelogenous leukemia. Biochem Biophys Res Commun.
323:728–730. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhong JS, Meng FY, Xu D, Zhou HS and Dai
M: Study on imatinib trough concentration, efficacy and their
relation in chronic myelocytic leukemia. Zhonghua Xue Ye Xue Za
Zhi. 33:177–182. 2012.(In Chinese). PubMed/NCBI
|
|
6
|
Chen WW, Meng FY, Zhong JS, Yin CX and
Wang ZX: Effects of hOCT1 and ABCB1 gene on the efficacy of
imatinib mesylate in chronic myelocytic leukemia. Zhonghua Yi Xue
Za Zhi. 92:1405–1408. 2012.(In Chinese). PubMed/NCBI
|
|
7
|
National Comprehensive Cancer Network:
Clinical Practice Guidelines in Oncology - Chronic Myelogenous
Leukemia. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdfAccessed.
October 09–2011
|
|
8
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cohen MH, Williams G, Johnson JR, Duan J,
Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, et al:
Approval summary for imatinib mesylate capsules in the treatment of
chronic myelogenous leukemia. Clin Cancer Res. 8:935–942.
2002.PubMed/NCBI
|
|
10
|
Deininger M, O'Brien SG, Guilhot F,
Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M,
Filian J, et al: International randomized study of interferon vs
STI571 (IRIS) 8-year follow up: Sustained survival and low risk for
progression or events in patients with newly diagnosed chronic
myeloid leukemia in chronic phase (CML-CP) treated with imatinib.
Blood. 114:11262009.
|
|
11
|
National Comprehensive Cancer Network:
Clinical Practice Guidelines in Oncology-Chronic Myelogenous
Leukemia. version 2. 2008.
|
|
12
|
Thomas J, Wang L, Clark RE and Pirmohamed
M: Active transport of imatinib into and out of cells: Implications
for drug resistance. Blood. 104:3739–3745. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Picard S, Titier K, Etienne G, Teilhet E,
Ducint D, Bernard MA, Lassalle R, Marit G, Reiffers J, Begaud B, et
al: Trough imatinib plasma levels are associated with both
cytogenetic and molecular responses to standard-dose imatinib in
chronic myeloid leukemia. Blood. 109:3496–3499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
White DL, Saunders VA, Dang P, Engler J,
Zannettino AC, Cambareri AC, Quinn SR, Manley PW and Hughes TP:
OCT-1-mediated influx is a key determinant of the intracellular
uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1
activity is the cause of low in vitro sensitivity to imatinib.
Blood. 108:697–704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Umehara KI, Iwatsubo T, Noguchi K and
Kamimura H: Functional involvement of organic cation transporter1
(OCT1/Oct1) in the hepatic uptake of organic cations in humans and
rats. Xenobiotica. 37:818–831. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
White DL, Saunders VA, Dang P, Engler J,
Venables A, Zrim S, Zannettino A, Lynch K, Manley PW and Hughes T:
Most CML patients who have a suboptimal response to imatinib have
low OCT-1 activity: Higher doses of imatinib may overcome the
negative impact of low OCT-1 activity. Blood. 110:4064–4072. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
White DL, Saunders VA, Dang P, Frede A,
Eadie L, Soverini S, Quarantelli F, Lin P, Thornquist M, Kim DW, et
al: CML patients with low OCT-1 activity achieve better molecular
responses on high dose imatinib than on standard dose. Those with
high OCT-1 activity have excellent responses on either dose: A TOPS
correlative study. Blood. 112:31872008.
|
|
18
|
Fojo T and Coley HM: The role of efflux
pumps in drug-resistant metastatic breast cancer: New insights and
treatment strategies. Clin Breast Cancer. 7:749–756. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kruh GD and Belinsky MG: The MRP family of
drug efflux pumps. Oncogene. 22:7537–7552. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mao Q and Unadkat JD: Role of the breast
cancer resistance protein (ABCG2) in drug transport. AAPS J.
7:E118–E133. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dai H, Marbach P, Lemaire M, Hayes M and
Elmquist WF: Distribution of STI-571 to the brain is limited by
P-glycoprotein-mediated efflux. J Pharmacol Exp Ther.
304:1085–1092. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Illmer T, Schaich M, Platzbecker U,
Freiberg-Richter J, Oelschlägel U, von Bonin M, Pursche S,
Bergemann T, Ehninger G and Schleyer E: P-glycoprotein-mediated
drug efflux is a resistance mechanism of chronic myelogenous
leukemia cells to treatment with imatinib mesylate. Leukemia.
18:401–408. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mahon FX, Belloc F, Lagarde V, Chollet C,
Moreau-Gaudry F, Reiffers J, Goldman JM and Melo JV: MDR1 gene
overexpression confers resistance to imatinib mesylate in leukemia
cell line models. Blood. 101:2368–2373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dohse M, Robey RW, Brendel C, Bates S,
Neubauer A and Scharenberg C: Efflux of the tyrosine kinase
inhibitors imatinib and nilotinib (AMN107) is mediated by ABCB1
(MDR1)-type P-glycoprotein. Blood. 108:13672006.
|
|
25
|
Tang K, Wong LP, Lee EJ, Chong SS and Lee
CG: Genomic evidence for recent positive selection at the human
MDR1 gene locus. Hum Mol Genet. 13:783–797. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim HJ, Hwang SY, Kim JH, Park HJ, Lee SG,
Lee SW, Joo JC and Kim YK: Association between genetic polymorphism
of multidrug resistance 1 gene and sasang constitutions. Evid Based
Complement Alternat Med. 6(Suppl 1): S73–S80. 2009. View Article : Google Scholar
|
|
27
|
Dulucq S, Bouchet S, Turcq B, Lippert E,
Etienne G, Reiffers J, Molimard M, Krajinovic M and Mahon FX:
Multidrug resistance gene (MDR1) polymorphisms are associated with
major molecular responses to standard-dose imatinib in chronic
myeloid leukemia. Blood. 112:2024–2027. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee CG, Tang K, Cheung YB, Wong LP, Tan C,
Shen H, Zhao Y, Pavanni R, Lee EJ, Wong MC, et al: MDR1, the
blood-brain barrier transporter, is associated with Parkinson's
disease in ethnic Chinese. J Med Genet. 41:e602004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maffioli M, Camós M, Gaya A,
Hernández-Boluda JC, Alvarez-Larrán A, Domingo A, Granell M,
Guillem V, Vallansot R, Costa D, et al: Correlation between genetic
polymorphisms of the hOCT1 and MDR1 genes and the response to
imatinib in patients newly diagnosed with chronic-phase chronic
myeloid leukemia. Leuk Res. 35:1014–1019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hitzl M, Drescher S, van der Kuip H,
Schäffeler E, Fischer J, Schwab M, Eichelbaum M and Fromm MF: The
C3435T mutation in the human MDR1 gene is associated with altered
efflux of the P-glycoprotein substrate rhodamine 123 from
CD56+ natural killer cells. Pharmacogenetics.
11:293–298. 2001. View Article : Google Scholar : PubMed/NCBI
|
